-
Feb 2024
Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.
DiabetesLatres E, Greenbaum CJ, Oyaski ML, Dayan CM, Colhoun HM, Lachin JM, Skyler JS, Rickels MR, Ahmed ST, Dutta S, Herold KC, Marinac M -
Dec 2023
Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
PLoS OneLord SM, Bahnson HT, Greenbaum CJ, Liljenquist DR, Virostko J, Speake C -
Nov 2023
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.
Nat CommunYlescupidez A, Bahnson HT, O'Rourke C, Lord S, Speake C, Greenbaum CJ -
Sep 2023
Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes.
Commun BiolNewman JRB, Long SA, Speake C, Greenbaum CJ, Cerosaletti K, Rich SS, Onengut-Gumuscu S, McIntyre LM, Buckner JH, Concannon P -
Sep 2023
Proinflammatory islet antigen reactive CD4 T cells are linked with response to alefacept in type 1 diabetes.
JCI InsightBalmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley PS, Cerosaletti K -
Aug 2023
OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals.
J Clin Endocrinol MetabYlescupidez A, Speake C, Pietropaolo SL, Wilson DM, Steck AK, Sherr JL, Gaglia JL, Bender C, Lord S, Greenbaum CJ -
Jun 2023
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry.
Lancet Diabetes EndocrinolChetboun M, Drumez E, Ballou C, Maanaoui M, Payne E, Barton F, Kerr-Conte J, Vantyghem MC, Piemonti L, Rickels MR, Labreuche J, Pattou F, Collaborative Islet Transplant Registry (CITR) Investigators study group, Greenbaum CJ -
May 2023
Approval of teplizumab: implications for patients.
Nat Rev EndocrinolSpeake C, Greenbaum CJ -
Mar 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Diabetes CareRussell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group -
Mar 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Diabetes CareWilson DM, Pietropaolo SL, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck AK, Vasudevan MM, McKay SV, Sherr JL, Herold KC, Dunne JL, Greenbaum CJ, Lord SM, Haller MJ, Schatz DA, Atkinson MA, Nelson PW, Pietropaolo M, Type 1 Diabetes TrialNet Study Group -
Jan 2023
Characterizing T cell responses to enzymatically modified beta cell neo-epitopes.
Front ImmunolNguyen H, Arribas-Layton D, Chow IT, Speake C, Kwok WW, Hessner MJ, Greenbaum CJ, James EA -
Oct 2022
IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.
JCI InsightSpeake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH -
Oct 2022
Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.
J Clin Endocrinol MetabO'Rourke C, Ylescupidez A, Bahnson HT, Bender C, Speake C, Lord S, Greenbaum CJ -
Sep 2022
From the prodromal stage of multiple sclerosis to disease prevention.
Nat Rev NeurolMarrie RA, Allegretta M, Barcellos LF, Bebo B, Calabresi PA, Correale J, Davis B, De Jager PL, Gasperi C, Greenbaum CJ, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger KL, Okuda DT, Ontaneda D, Postuma RB, Quandt JA, Roman S, Saidha S, Sormani MP, Strum J, Valentine P, Walton C, Zackowski KM, Zhao Y, Tremlett H -
Jul 2022
IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation.
Front ImmunolLambert K, Diggins KE, Jones BE, Hundhausen C, Maerz MD, Hocking AM, Sanda S, Greenbaum CJ, Linsley PS, Cerosaletti K, Buckner JH